The team

Our people are our strength

Executive leadership team

Oriol Casanovas, PhD.
Co-Founder & interim CEO

Dr. Casanovas is an internationally renowned biomedical researcher with extensive knowledge and experience in basic and translational research focused on determining the consequences of adaptation and resistance to therapies against cancer.

Gabriela Jiménez, PhD.
Co-Founder & COO

Dr. Jiménez has a PhD in Biomedicine from the University of Barcelona and studies BSM, EADA business school and IESE. She is experienced in business development, drug development and biomarker discovery.

Juana Flores, PhD, MBA

15+ years in corporate strategy and +15 in research
Launched more than 10 innovative products and contributed to 4 M&A..

Advisor team

Itziar Canamasas, PhD.
Business Advisor & Chairwoman

Dr. Canamasas is a highly experienced pharmaceutical executive with a PhD in Tumor Genetics from the University of Mainz and studies at Harvard Business School and IMD Business School.

Bart Huisken, MBA.
Co-Founder & Business Strategy

Business Angel, NED and strategic advisor
Co-founded 7 businesses over 20+ years

Richard Roberts, PhD.
Medicinal Chemistry Advisor

20+ years in drug development

Scott Wilhem
Product Development Strategic Advisor

18 years as the director of oncology discovery at Bayer

Mark Tebbe
Operational and Chemistry Advisor

20+ years in drug development

Todd Snowden
IVD Strategic & Commercial Development Advisor

25+ years in MedTech. IVD expert & biomarker lead

Research team

Our academic founders have played a key role in demonstrating that resistance to cancer therapy occurs in response to adaptive mechanisms of tumor cells.

We are part of the Program Against Cancer Therapeutic Resistance (ProCURE)

We research resistance mechanisms and tumor malignization

We are always looking for new talent to join our team